Viral Vector Manufacturing Market Size is projected to grow between 2022 to 2028 due to the prevalence of target diseases and the availability of funding for gene therapy development. The presence of viral vector gene therapies for the treatment of cancers and rare diseases will boost the growth in the global market.
Viral vector gene therapy has shown immense promise that is slated to help mitigate the impact of infectious diseases and viruses. Viral vector gene therapies use modified viruses as drug-delivery vehicles to introduce regulatory RNAs, encoding genes and other therapeutic substances into cells. Viruses have become monumental owing to their ability to enter cells and gain access to highly specific and hard-to-reach cells. Pharmaceutical companies are expected to use viral vector gene therapies to treat a host of diseases and help disease prevention through immunization.
Based on type, adeno associated viral vectors will expand during the forecast period. A notable surge in clinical trials on the back of high accuracy in a delivery gene will augur well for the business outlook. AAV vector is emerging as a leading technology that can lead to disease modification in several monogenic disorders.
In terms of disease, cancer will account for a considerable share of market led by soaring cases globally. Viruses have become effective as a vector for gene therapy production against various cancer types. According to the International Agency for Research on Cancer (IARC), 1 in 5 people develop cancer during their lifetime. Moreover, over 50 million people are living within 5 years of cancer diagnosis, while more than 19,292,789 new cases were witnessed in 2020. These trends have led to investments in clinical trials and the development of viral vector-based cancer drugs.
North America viral vector manufacturing market share is likely to witness notable growth till 2028. Pharmaceutical and biotech companies are likely to invest in adenoviral vectors and retroviral vectors amidst escalating cases of genetic disorders and infectious diseases. Additionally, governments and research organizations have upped focus on gene therapy and vaccine development. Notably, regulatory approvals for advanced therapies have contributed to regional growth.
The competitive landscape of global market suggests leading companies will focus on mergers & acquisitions, product launches, R&D activities and technological advancements. Oxford BioMedica Plc., Merck KGaA, Thermo Fisher Scientific, Spark Therapeutics Inc., Fujifilm Diosynth Biotechnologies, Kaneka Corporation, Cobra Biologics, Sanofi SA and Novasep Inc. are some of the key players in the landscape.
In January 2021, Thermo Fisher Scientific announced around USD 880 million acquisition of Belgium-based Henogen SA, Novasep’s viral victor manufacturing business. Thermo Fisher is striving to foster its capabilities for cell and gene vaccines and therapies.
With the COVID-19 pandemic signifying the prospect of vaccine development, viral vector manufacturing has received a massive uptick. According to the WHO, at least 48 candidate vaccines are in a human trial, while around 10 are in phase III trials. Leading companies have also developed effective packaging cell line systems for several viral vector systems, including adenoviruses and adeno-associated viruses. Governments are likely to invest in engineered viruses to curb the impact of the coronavirus in the global economy.
The rising prevalence of infectious diseases, cancer and genetic disorders will encourage stakeholders to boost clinical studies using viral vectors. Research and development activities in cell and gene therapy and gene editing will also augur well for the global outlook.
Market, By Type
Market, By Disease
Market, By Application
Market, By End-user
The above information is provided for the following regions and countries: